Viewing Study NCT05013892


Ignite Creation Date: 2025-12-24 @ 3:33 PM
Ignite Modification Date: 2025-12-26 @ 7:49 AM
Study NCT ID: NCT05013892
Status: RECRUITING
Last Update Posted: 2025-12-10
First Post: 2021-08-06
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: NTS-WBRT in Brain Metastases
Sponsor: Massachusetts General Hospital
Organization:

Study Overview

Official Title: Phase II Trial of Normal Tissue Sparing Whole Brain Radiation Therapy (NTS-WBRT) in Patients With Brain Metastases
Status: RECRUITING
Status Verified Date: 2025-12
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This research is being done to assess the quality of life and symptom burden in participants who receive (normal tissue sparing whole brain radiation therapy (NTS-WBRT).

This research study involves:

* NTS-WBRT (normal tissue sparing whole brain radiation therapy)
* Memantine standard of care drug
Detailed Description: This is a Phase 2 trial testing the safety and effectiveness of NTS-WBRT (normal tissue sparing whole brain radiation therapy) in treating brain metastases.

NTS-WBRT is a targeted radiation therapy that further reduces radiation dose to tissue that does not need radiation therapy treatment.

The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.

It is expected that about 41 people will take part in this research study.

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: True
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: